Analysis of antitumor effect against human melanoma by using STAT3 inhibitor (human-rR9-GRIM19)

• Project/Area Number: 25860941
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Dermatology
• Research Institution: University of Yamanashi
• Principal Investigator: OKAMOTO Takashi 山梨大学, 総合研究部, 助教 (30402043)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
• Keywords: 腫瘍免疫 / STAT3 / GRIM-19 / stat3 / メラノーマ / 悪性黒色腫 / R9

Outline of Final Research Achievements

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is common in many human and murine cancer cells, and its activation leads to cellular transformation. STAT3 pathway inhibitors have been reported to suppress cancer growth. Previously, We generated an R9-PTD-containing GRIM-19 fusion protein (rR9-GRIM19) and successfully induced overexpression in the cytoplasm of cancer cells. In murine model, rR9-GRIM19 suppressed cell growth in vitro and in vivo. In this research we generated human-rR9-GRIM19 protein and analyze the antitumor effect of this protein against human melanoma cell line.